Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;62(10):589-596.
doi: 10.1002/gcc.23150. Epub 2023 May 24.

The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing

Melanie A Jones  1 , Kirsten M Timms  1 , Shanell Hatcher  1 , Elizabeth S Cogan  1 , Matthew S Comeaux  1 , Michael Perry  1 , Brian Morris  1 , Brad Swedlund  1 , Cathy E Elks  2 , Pierre Lao-Sirieix  2 , Simon Dearden  2 , Coumaran Egile  2 , Jessica S Brown  2 , Elizabeth A Harrington  2 , Darren Hodgson  2 , Matt Stern  1 , Thomas P Slavin  1 , Debora Mancini-DiNardo  1
Affiliations

The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing

Melanie A Jones et al. Genes Chromosomes Cancer. 2023 Oct.

Abstract

Background: Approximately half of ovarian tumors have defects within the homologous recombination repair pathway. Tumors carrying pathogenic variants (PVs) in BRCA1/BRCA2 are more likely to respond to poly-ADP ribose polymerase (PARP) inhibitor treatment. Large rearrangements (LRs) are a challenging class of variants to identify and characterize in tumor specimens and may therefore be underreported. This study describes the prevalence of pathogenic BRCA1/BRCA2 LRs in ovarian tumors and discusses the importance of their identification using a comprehensive testing strategy.

Methods: Sequencing and LR analyses of BRCA1/BRCA2 were conducted in 20 692 ovarian tumors received between March 18, 2016 and February 14, 2023 for MyChoice CDx testing. MyChoice CDx uses NGS dosage analysis to detect LRs in BRCA1/BRCA2 genes using dense tiling throughout the coding regions and limited flanking regions.

Results: Of the 2217 PVs detected, 6.3% (N = 140) were LRs. Overall, 0.67% of tumors analyzed carried a pathogenic LR. The majority of detected LRs were deletions (89.3%), followed by complex LRs (5.7%), duplications (4.3%), and retroelement insertions (0.7%). Notably, 25% of detected LRs encompassed a single or partial single exon. This study identified 84 unique LRs, 2 samples each carried 2 unique LRs in the same gene. We identified 17 LRs that occurred in multiple samples, some of which were specific to certain ancestries. Several cases presented here illustrate the intricacies involved in characterizing LRs, particularly when multiple events occur within the same gene.

Conclusions: Over 6% of PVs detected in the ovarian tumors analyzed were LRs. It is imperative for laboratories to utilize testing methodologies that will accurately detect LRs at a single exon resolution to optimize the identification of patients who may benefit from PARP inhibitor treatment.

Keywords: PARP inhibitors; companion diagnostic testing; copy number variants; deletion; duplication; homologous recombination deficiency; large rearrangements; next-generation sequencing; ovarian cancer; tumor testing.

PubMed Disclaimer

References

REFERENCES

    1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, 2023.
    1. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296.
    1. Gorringe KL, Cheasley D, Wakefield MJ, et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020;156(3):552-560.
    1. Zalaznick H, Clegg B, Cogan E, et al. Rates of homologous recombination deficiency across different subtypes of ovarian cancer and in pre- and post-neoadjuvant chemotherapy tumor samples (139.5). Soc Gynecol Oncol. 2022;166:S86-S87.
    1. Iijima M, Banno K, Okawa R, et al. Genome-wide analysis of gynecologic cancer: the cancer genome atlas in ovarian and endometrial cancer. Oncol Lett. 2017;13(3):1063-1070.

Publication types